MedPharm
MedPharm has announced the opening of a new £5 million GMP facility in Guildford as it strives to double turnover and increase market share over the next five years.
Dr. Andrew Muddle, CEO, commented: “The opening of the new site is a huge milestone for our business. We can now offer a true one stop shop for formulation development, all provided in-house. From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements. In particular, the bespoke clinical trial supplies production facility, regulated by state-of-the-art monitoring systems, will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms. These include liquids, semi-solid gels, creams and ointments as well as inhaled products, sprays and transdermal patches, to name but a few.”
The investment adds a new microbiology laboratory, cleanroom suites, a dedicated ICH stability testing area and quality control and performance testing laboratories to support Phase I and II clinical manufacture. The facility also allows for the manufacture of highly potent compounds up to OEB 4 level, with a manufacturing batch scale of up to 50 kg and primary packaging, labelling and randomisation services.
“This new capability allows MedPharm to ensure a smooth transfer from development and preclinical studies to clinical manufacturing by taking all the services in-house on one site. This has the potential to significantly decrease project timelines and costs for clients,” added MedPharm’s CSO and COO, Professor Marc Brown.
The expansion was funded partly with assistance from Lloyds Commercial Banking.
MedPharm Ltd, +44 1483 457580, www.medpharm.co.uk.